If you're a concerned citizen who's worked hard, lived frugally, saved, and invested what you could along the way, you need to check this out as soon as possible.

Julianne Bruno Biography and Net Worth

COO of CRISPR Therapeutics

Julianne Bruno, M.B.A., serves as our Chief Operating Officer. She previously served as Senior Vice President and Head of Programs & Portfolio Management at CRISPR Therapeutics since March 2023. During her time at CRISPR Therapeutics since joining the Company in April 2019, she has taken on positions of increasing responsibility, including leading the hemoglobinopathies partnership with Vertex through the early clinical stage through approval. In addition, she has been responsible for program leadership of our immuno-oncology assets and the program management function across our franchises. Prior to joining CRISPR Therapeutics, Ms. Bruno worked at McKinsey & Company from August 2015 to March 2019 where she was a leader in the biotech practice and served a number of biotechnology companies on a wide range of commercial topics. She received her M.B.A. from The Wharton School and also holds an A.B. from Princeton University.

What is Julianne Bruno's net worth?: The estimated net worth of Julianne Bruno is at least $318,701.25 as of June 21st, 2024. Ms. Bruno owns 6,745 shares of CRISPR Therapeutics stock worth more than $318,701 as of September 30th. This net worth evaluation does not reflect any other investments that Ms. Bruno may own. Learn More about Julianne Bruno's net worth.
How do I contact Julianne Bruno?: The corporate mailing address for Ms. Bruno and other CRISPR Therapeutics executives is BAARERSTRASSE 14, ZUG V8, CH-6300. CRISPR Therapeutics can also be reached via phone at (141) 561-3277 and via email at [email protected]. Learn More on Julianne Bruno's contact information.
Has Julianne Bruno been buying or selling shares of CRISPR Therapeutics?: Julianne Bruno has not been actively trading shares of CRISPR Therapeutics during the past quarter. Most recently, Julianne Bruno sold 3,366 shares of the business's stock in a transaction on Friday, June 21st. The shares were sold at an average price of $56.09, for a transaction totalling $188,798.94. Following the completion of the sale, the chief operating officer now directly owns 6,745 shares of the company's stock, valued at $378,327.05. Learn More on Julianne Bruno's trading history.
Who are CRISPR Therapeutics' active insiders?: CRISPR Therapeutics' insider roster includes Bradley Bolzon (Director), Julianne Bruno (COO), Kurt Emster (Director), Tony Ho (VP), James Kasinger (General Counsel), Lawrence Klein (COO), Samarth Kulkarni (CEO), Rodger Novak (President), and Michael Tomsicek (CFO). Learn More on CRISPR Therapeutics' active insiders.
Are insiders buying or selling shares of CRISPR Therapeutics?: In the last year, insiders at the sold shares 11 times. They sold a total of 157,358 shares worth more than $10,596,633.51. The most recent insider tranaction occured on June, 21st when COO Julianne Bruno sold 3,366 shares worth more than $188,798.94. Insiders at CRISPR Therapeutics own 4.1% of the company. Learn More about insider trades at CRISPR Therapeutics.
Information on this page was last updated on 6/21/2024.

Julianne Bruno Insider Trading History at CRISPR Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
6/21/2024	Sell	3,366	$56.09	$188,798.94	6,745

Julianne Bruno Buying and Selling Activity at CRISPR Therapeutics

CRISPR Therapeutics Company Overview

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.

Today's Range

Now: $47.10

$46.55

$47.68

50 Day Range

MA: $49.28

$44.62

$58.50

2 Week Range

Now: $47.10

$37.55

$91.10

Volume

641,541 shs

Average Volume

1,488,318 shs

Market Capitalization

$4.00 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.68

Most hated message on Wall Street

From Stansberry Research | Ad